Biomagnetics Diagnostics Corp. engages in the provision of medical and biotechnology devices. The company is headquartered in Orangevale, California. The company went IPO on 2002-04-09. The Company’s diagnostics system focuses on real-time testing for the actual presence of the virus or toxin or disease itself and not for antibodies produced by the body's immune system which may take anywhere from weeks to months to appear. The Company’s products include High Throughput Screening - Magnetic Testing Platform (HTS-MTP) and Integrity Optical Biosensor (IOBS). Its HTS-MTP is designed to detect both qualitative chemical identification of the elements present in a substance and quantitative number of specific elements in a substance results from a single test. The firm triggered optical biosensor that is based on protein-receptor binding that brings two or more optically tagged receptors into close proximity using planar optical waveguides, thereby triggering fluorescence changes identified almost instantly by tiny on-board detectors.
최신 재무제표(Form-10K)에 따르면, Pan Pacific International Holdings Corporation의 총 자산은 $0이며, 순손실입니다.
BMGP의 주요 재무 비율은 무엇인가요?
Pan Pacific International Holdings Corporation의 유동비율은 0이고, 순이익률은 0, 주당 매출은 $0입니다.
Biomagnetics Diagnostics Corp의 매출은 부문 또는 지역별로 어떻게 나뉘나요?
Pan Pacific International Holdings Corporation 주요 수익원은 Domestic이며, 최신 수익 발표에서 수익은 1,896,113,000,000입니다. 지역별로는 Japan이 Pan Pacific International Holdings Corporation의 주요 시장이며, 수익은 1,896,113,000,000입니다.
Biomagnetics Diagnostics Corp은 수익성이 있나요?
no, 최신 재무제표에 따르면 Pan Pacific International Holdings Corporation의 순손실은 $0입니다.
Biomagnetics Diagnostics Corp에 부채가 있나요?
no, Pan Pacific International Holdings Corporation의 부채는 0입니다.
Biomagnetics Diagnostics Corp의 발행 주식은 몇 주인가요?
Pan Pacific International Holdings Corporation의 총 발행 주식은 0주입니다.